Arthritis  >>  oxycodone controlled release  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxycodone controlled release / Generic mfg.
NCT00399048: An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)

Completed
3
140
US
OROS hydromorphone HCL ; OxyContin
Alza Corporation, DE, USA
Osteoarthritis, Knee, Osteoarthritis, Hip
 
05/01
NCT00361504: A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Completed
3
1123
US, Canada
Oxycodone CR, Tapentadol (CG5503) ER, CG5503
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH
Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain, Pain
07/08
07/08
NCT00784277: A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

Completed
3
597
US
oxycodone CR, oxycodone IR, Tapentadol ER (CG5503), Tapentadol IR (CG5503), placebo
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH
Joint Diseases, Arthritis, Osteoarthritis
07/09
07/09

Download Options